High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

PURPOSE: We sought to understand the clinical course and molecular phenotype of patients who showed disease progression after programmed cell death ligand 1 (PD-L1) inhibitor treatment but subsequently responded to PD-1 inhibitor treatment. We also explored the response to PD-1-axis targeted therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Kong, Haiying, Luo, Linxiang, Han, Shuiyun, Lei, Tao, Yu, Haifeng, Guo, Na, Li, Cong, Peng, Shuailing, Dong, Xiaowu, Yang, Haiyan, Wu, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722342/
https://www.ncbi.nlm.nih.gov/pubmed/34980000
http://dx.doi.org/10.1186/s12885-021-09028-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722342/
https://www.ncbi.nlm.nih.gov/pubmed/34980000
http://dx.doi.org/10.1186/s12885-021-09028-4

Ejemplares similares